清肝滋肾方调节肥胖型高血压Irisin水平及改善代谢紊乱的临床研究

Clinical Study on Qinggan Zishen Formula to Regulate Irisin Levels and Mitigate Metabolic Disorders in Obesity-Related Hypertension

    摘要
  • 摘要:
      目的  观察清肝滋肾方联合常规降压西药治疗对肥胖型高血压患者的鸢尾素(Irisin)表达水平及代谢指标的影响。
      方法  选择符合纳入标准的肥胖型高血压阴虚阳亢证患者80例, 随机分为观察组及对照组各40例。对照组给予生活方式干预及持续常规西医治疗, 观察组在对照组治疗基础上加用清肝滋肾方, 疗程均为8周, 观察2组患者治疗前后中医证候积分、临床疗效、人体测量学指标收缩压(Systolic blood pressure, SBP)、舒张压(Diastolic blood pressure, DBP)、体质量(Weight, WT)、腰围(Waist circumference, WC)、代谢特征指标空腹血糖(Fasting blood glucose, FBG)、总胆固醇(Total cholesterol, TC)、甘油三酯(Triglyceride, TG)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol, LDL-C)、鸢尾素(Irisin)、血清脂肪因子脂联素(Adiponectin, ADP)及瘦素(Leptin, LEP)以及安全性指标的变化情况。
      结果  治疗后, 2组中医证候积分明显下降(P < 0.05, P < 0.01), 且观察组在改善头痛眩晕、急躁易怒、潮热盗汗、腰膝酸软、口燥咽干、五心烦热、便秘尿黄症状及总积分方面优于对照组(P < 0.05, P < 0.01);观察组中医临床疗效优于对照组(P < 0.05);观察组Irisin水平明显升高(P < 0.01), 优于对照组(P < 0.01);观察组SBP、DBP明显下降(P < 0.05), 优于对照组(P < 0.05);2组WT、WC、TC、TG、LDL-C、ADP、LEP水平均明显改善(P < 0.05, P < 0.01), 观察组优于对照组(P < 0.05)。治疗期间2组均未出现明显不良反应。
      结论  清肝滋肾方联合常规降压西药能调节肥胖型高血压阴虚阳亢证患者Irisin表达，改善代谢紊乱。

     

    Abstract:
      OBJECTIVE  To observe the effects of Qinggan Zishen formula combined with conventional antihypertensive western medicine treatment on the expression level of irisin and metabolic indexes in patients with obesity-related hypertension.
      METHODS  A total of 80 obesity-related hypertension patients with yin deficiency and yang hyperactivity who met the inclusion criteria were selected and randomly divided into 40 cases each in the observation group and the control group. In the control group, patients were given lifestyle interventions and continuous conventional western medical treatment, while the observation group was treated with oral administration of traditional Chinese medicine (TCM) decoction pieces - Qinggan Zishen formula based on the therapies in the control group. The treatment course lasted eight weeks. In addition, before and after the treatment, we observed the changing levels of TCM syndrome score, clinical efficacy, anthropometric indexes systolic blood pressure (SBP), diastolic blood pressure (DBP), weight (WT), waist circumference (WC), metabolic indexes fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), irisin, adipokines adiponectin (ADP) and leptin (LEP), as well as safety indicators.
      RESULTS  After treatment, the TCM syndrome scores of both groups were decreased significantly (P < 0.05, P < 0.01), but the result of observation group was better than that of control group in reliving the syndromes of headache and dizziness, irritability, tidal fever and night sweats, soreness and weakness of waist and knees, dry mouth and throat, feverish sensations in palms, soles and chest, constipation, as well as dark urine. Besides, the total TCM syndrome scores of observation group showed better results than those of the control group (P < 0.05, P < 0.01). In addition, the TCM clinical efficacy of the observation group was better than that of the control group (P < 0.05). The irisin level was significantly higher in the observation group (P < 0.01), so its result was better than that of the control group (P < 0.01). The levels of SBP and DBP were significantly reduced in the observation group (P < 0.05), which also showed better results than those of the control group (P < 0.05). Although both groups' results of WT, WC, TC, TG, LDL-C, ADP, and LEP were notably changed in a good way (P < 0.05, P < 0.01), the observational group showed better results than those of the control group (P < 0.05). No significant adverse reactions were observed in both groups during the treatment course.
      CONCLUSION  Qinggan Zishen formula combined with conventional antihypertensive western medicine can regulate irisin expression and mitigate metabolic disorders in obesity-related hypertension patients with yin deficiency and yang hyperactivity.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回